EMBC
Strong BuyUnloved QualityFLAGEmbecta Corp. · Healthcare · United States · $286M · Avg Vol: $8M/d
Unloved Quality: Strong and cheap, but the market has not turned yet. Patience required.
Insufficient evidence for a screen-pass. Embecta Corp.: fails the quant gate on momentum (Q78/V85/M21; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
ABOUT EMBECTA CORP.
Read
Embecta Corp. is a pure-play global medical device company dedicated exclusively to diabetes care, offering a comprehensive portfolio of insulin delivery solutions including pen needles and syringes. Spun off from Becton Dickinson, the company holds a leading market position globally, leveraging extensive distribution networks and established brand trust among patients and healthcare providers. This specialized focus ensures deep expertise and market penetration in a critical healthcare segment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 1.1B | 1.1B | -1.5% | 1.0B | 1.0B | 1.1B | 0.1% |
| EPS | 3.92 | 1.23 | 1.36 | 1.64 | -25.2% | 1.47 | 1.02 | 0.98 | -22.7% |
| Shares | 57.1M | 57.3M | 57.7M | 58.5M | +2.5% | 56.7M | — | — | — |
| Debt | 1.6B | 1.6B | 1.6B | 1.4B | -4.5% | 1.5B | — | — | — |
| Equity | -891.4M | -821.7M | -738.9M | -651.2M | — | — | — | — | — |
| Op CF | 412.2M | 67.7M | 35.7M | 191.7M | -22.5% | 174.1M | — | — | — |
| Inv CF | -24.0M | -26.5M | -15.8M | -9.3M | — | — | — | — | — |
| Fin CF | -48.0M | -48.7M | -73.4M | -226.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EMBC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EMBC | Embecta Corp.(you) | $286M | 88 | Strong Buy |
| UTMD | Utah Medical Products, Inc. | $232M | 94 | Strong Buy |
| PDEX | Pro-Dex, Inc. | $200M | 95 | Strong Buy |
| SMTI | Sanara MedTech Inc. | $318M | 68 | Buy |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| OSUR | OraSure Technologies, Inc. | $248M | 33 | Sell |
| NVST | Envista Holdings Corporation | $4.4B | 85 | Strong Buy |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
| MMSI | Merit Medical Systems, Inc. | $5.4B | 82 | Strong Buy |
| ATRC | AtriCure, Inc. | $2.5B | 64 | Hold |
Peer medians: ROE -30.9% · P/E 25.2x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.